

form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Substitute Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Applicant's Attorney submits the following amendments to comply with 37 C.F.R. §1.825:

In the Specification

Please insert the attached "Substitute Sequence Listing" (sheets 1/6 through 6/6), and comprising SEQ ID NOS: 1 through 21, into the above-referenced application.

In addition to the above changes, please amend the specification as follows:

At page 4, replace lines 8-9 with the following:

A¹ --Figs. 2A-2G illustrate the OPMD (GCG)_n expansion sizes and sequence of the mutation site (SEQ ID NO:1), nucleic acid mutation site; SEQ ID NO:2: nucleic acid mutation site without insertion; SEQ ID NO:3-9, nucleic acid mutation site with 1 through 7 (GCG) insertions, respectively; SEQ ID NO:10, amino acid sequence encoded by the nucleic acid mutation site; SEQ ID NO: 11-17, amino acid sequence encoded by the nucleic acid mutation site with 1 through 7 Alanine insertions, respectively);--

At page 4, replace lines 12-13 with the following:

A² --Figs. 4A-4E illustrate the nucleotide sequence of human poly(A) binding protein II (hPAB II) (SEQ ID NO:18).--

At page 11, replace lines 12-14 with the following:

A³ --The primers used to amplify the PAB II mutated region were: 5'-CGCAGTGCCCCGCCTTAGA-3' (SEQ ID NO:19) and 5'-ACAAGATGGCGCCGCCCGCCCGGC-3' (SEQ ID NO:20)--.